Human genes associated with brain-related diseases are being discovered at an accelerating pace. A major challenge is the identification of the mechanisms through which these genes act, and of potential therapeutic strategies. To elucidate such mechanisms in human cells, we are leveraging a CRISPR-based platform for genetic screening that we recently co-developed. Our approach relies on CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), in which a catalytically dead version of the bacterial Cas9 protein recruits transcriptional repressors or activators, respectively, to endogenous genes to control their expression, as directed by a small guide RNA (sgRNA). Complex libraries of sgRNAs enable us to conduct genome-wide loss-of-function and gain-of-function screens in mammalian cells. We have adapted this strategy for use in human iPSC-derived neurons and glia, enabling us to conduct genetic modifier screens for disease-relevant cellular phenotypes in patient-derived cells with familial mutations and isogenic CRISPR-corrected controls. Our first screens are uncovering cellular mechanisms controlling neuronal aggregation of the protein tau, which is a hallmark of Alzheimer’s Disease and other tauopathies.
A CRISPR Approach to Neurodegenerative Diseases
Assistant Professor, Institute for Neurodegenerative Diseases
University of California, San Francisco
We strive to make our events accessible and inclusive. The Innovative Genomics Institute Building is ADA accessible, and has a lactation room that visitors can use. For disability accommodation information and requests and/or access to the lactation room, please contact Kristy Nordahl at firstname.lastname@example.org or 510-664-7110.